Understanding The Landscape of Weight Loss Drugs
Imagine your body is like a big city, and the hormones are like messengers that help control different things in the city, like how hungry you feel or how much energy you use.
Brain and pancreas targeted drugs: GLP-1 drugs like semaglutide and oral semaglutide target the pancreas and brain, helping the pancreas release more insulin, making you feel less hungry, and slowing down digestion, but they may cause side effects such as nausea, vomiting, diarrhea, and constipation.
- Tirzepatide, a GLP-1 and GIP drug, works similarly but also targets the gut, potentially leading to stronger effects on weight loss and blood sugar control.
Brain, pancreas, and liver targeted drugs: GLP-1 and glucagon drugs, such as survodutide, mazdutide, pemvidutide, and efinopegdutide, target the pancreas, liver, and brain, combining the effects of GLP-1 on blood sugar control and appetite with glucagon's ability to increase energy use and fat burning.
- Retatrutide, a GLP-1, GIP, and glucagon drug, takes this approach a step further by targeting the gut as well, potentially leading to even greater improvements in weight loss, blood sugar control, and energy balance, although it may cause mild to moderate gastrointestinal side effects.
Muscle targeted drugs: Bimagrumab targets muscles to help build muscle and burn fat, but it may cause side effects like diarrhea and transiently elevated pancreatic and liver enzymes.
What is the strongest weight loss prescription pill?
According to a literature review published in the Journal of Obesity in February 2024, Semaglutide is the most popular current treatment for weight loss while Tirzepatide is the strongest weight loss prescription pill by body weight reduction percentage. Future treatments like Retatrutide and Cagrisema may provide even better results, with Orforglipron offering a convenient oral alternative.
- Most popular: Semaglutide (FDA approved June 2021) known as Ozempic of Wegovy is a GLP-1 receptor agonist that results in a 15-17% mean weight loss at 68 weeks when taken as 2.4 mg once weekly. It is well-regarded for its effectiveness in both weight loss and blood sugar control, making it a popular choice for managing obesity and type 2 diabetes.
- Strongest available: Tirzepatide (FDA approved May 2022) known as Mounjaro or Zepbound is a dual GLP-1 and GIP receptor agonist. It surpasses Semaglutide in terms of weight loss, achieving 16-22.5% weight loss over 72 weeks with doses of 5-15 mg once weekly.
Promising new drugs coming to the market
- Better than both Semaglutide and Tirzepatide: Retatrutide is a GLP-1/GIP/glucagon triple agonist currently in Phase 3 trials. It has shown even greater potential than both Semaglutide and Tirzepatide, with up to 24.2% weight loss compared over 48 weeks at doses of 1-12 mg once weekly. Its trials are expected to complete by May 2026.
- Fastest body weight reduction in a shorter period: Cagrisema is a dual GLP-1 and amylin agonist in Phase 1 trials. It has shown up to 17.1% weight loss compared to 9.5% with Semaglutide alone over 20 weeks with doses of 2.4 mg/2.4 mg once weekly. This positions Cagrisema as potentially comparable to Semaglutide, with the added benefits of amylin agonism. The expected completion date for its trials is October 2026.
- Promising oral alternative: Orforglipron is a GLP-1 receptor agonist in Phase 2 trials, demonstrating up to 14.7% weight loss over 36 weeks at doses of 12-45 mg once daily. While it is slightly less effective than Semaglutide in terms of maximum weight loss, its oral administration may provide a more convenient alternative for some patients. The trials are expected to complete by September 2027.
| Drug/Molecule Name | Results | Current Phase | Expected Completion Date |
|---|---|---|---|
| GLP-1 receptor agonists | |||
| Semaglutide | 15-17% mean weight loss at 68 weeks with 2.4 mg once weekly | Approved | - |
| Oral semaglutide | 17.4% weight loss at 68 weeks with 50 mg once daily | Phase 3 | Completed |
| Orforglipron | Up to 14.7% weight loss at 36 weeks with 12-45 mg once daily | Phase 2 | September 2027 |
| Danuglipron | Up to 11.7% weight loss at 32 weeks with 40-200 mg twice daily | Phase 2b | Completed |
| Dual GLP-1 and GIP receptor agonists | |||
| Tirzepatide | 16-22.5% weight loss at 72 weeks with 5-15 mg once weekly | Approved | - |
| GLP-1/glucagon co-agonists | |||
| Survodutide | Up to 18.7% weight loss at 46 weeks with 0.6-4.8 mg once weekly | Phase 3 | Completed |
| Mazdutide | Up to 11.3% weight loss at 24 weeks with 3-6 mg once weekly 15.4% placebo-adjusted weight loss at 24 weeks with 9 mg once weekly | Phase 3 (4-6 mg), Phase 2 (9 mg) | April 2024 (4-6 mg), September 2025 (9 mg) |
| Pemvidutide | Up to 15.6% weight loss at 48 weeks with 2.4 mg once weekly | Phase 2 | Completed |
| Efinopegdutide | Up to 11.8% weight loss vs. 7.5% with liraglutide at 26 weeks with 5-10 mg once weekly | Phase 2 | Completed |
| Retatrutide | Up to 24.2% weight loss at 48 weeks with 1-12 mg once weekly | Phase 3 | May 2026 |
| Amylin analogues | |||
| Cagrilintide | 6-10.8% weight loss vs. 9% with liraglutide at 26 weeks with 0.3-4.5 mg once weekly | Phase 2 | Completed |
| Cagrisema | Up to 17.1% weight loss vs. 9.5% with semaglutide alone at 20 weeks with 2.4 mg/2.4 mg once weekly | Phase 1 | October 2026 |
| Neuropeptide Y receptor type 2 agonists | |||
| Y14 peptide (PYY analogue) | 2.9-3.6 kg weight loss at 31 days, with a 38-55% reduction in food intake | Phase 1 | Completed |
| Activin type II receptor blockers | |||
| Bimagrumab | 6.5% weight loss at 48 weeks with 10 mg/kg intravenously every 4 weeks | Phase 2 | September 2025 |
Comparing Weightloss Drugs by Side Effects
Semaglutide has a high incidence of nausea, vomiting, diarrhea, and constipation, Tirzepatide presents fewer side effects overall but still needs monitoring. Overall, Retatrutide shows great promise with a lower % of side effects at a lower start dose but higher on average side effects % reported at therapeutic and maintenance doses that could lead to discontinuation of the program.
Nausea is the most common side effect across nearly all weight loss drugs. Nausea typically occurs during the initial phase of treatment and may diminish as the body adjusts to the medication.
Vomiting varies widely among these drugs. Tirzepatide has a lower incidence, with 8-12% of users experiencing vomiting, making it more tolerable in this aspect. Retatrutide shows a vomiting rate ranging from 3-26%, which is quite variable.
Diarrhea is another prevalent side effect, affecting up to 41% of users in some cases, such as Bimagrumab. The frequency of diarrhea is notable in Mazdutide (up to 40%) and Orforglipron (up to 36%).
Constipation is less common but still notable. Frequencies reach up to 32% in Orforglipron users. For Semaglutide (oral), constipation affects 28% of users, indicating a considerable impact. Tirzepatide has a lower incidence of 12-17%, making it a bit easier to manage. Retatrutide ranges from 6-17%, showing variability but generally lower than Semaglutide. Constipation can often be managed with dietary adjustments and increased fluid intake.
| ug/Molecule Name (Dose) | Nausea (%) | Vomiting (%) | Diarrhea (%) | Constipation (%) | Serious Adverse Effects (%) | Adverse Effects Leading to Discontinuation (%) |
|---|---|---|---|---|---|---|
| Bimagrumab (10 mg/kg IV) | 11% | - | 41% | - | 8% | 14% |
| Cagrilintide (0.3-4.5 mg SC OW) | 20-47% | 6-8% | 7-18% | 8-21% | 1-7% | 1-6% |
| Tirzepatide (5-15 mg SC OW) | 25-33% | 8-12% | 19-23% | 12-17% | 5-9% | 4-7% |
| Retatrutide (1-12 mg SC OW) | 14-60% | 3-26% | 2-25% | 6-17% | 0-8% | 2-17% |
| Semaglutide (oral) (50 mg PO OD) | 52% | 24% | 27% | 28% | 8-11% | 6-13% |
| Pemvidutide (ALT-801) (1.2-2.4 mg SC OW) | 26-60% | 6-28% | 8-19% | 13-23% | 0-1% | 0-20% |
| Mazdutide (3-9 mg SC OW) | 21-41% | 13-28% | 19-31% | - | 0-7% | 0-2% |
| Orforglipron (12-45 mg PO OD) | 37-58% | 14-32% | 3-36% | 13-32% | 0-11% | 10-21% |
| Efinopegdutide (5-10 mg SC OW) | 51-68% | 20-55% | 14-20% | 12-18% | 2-6% | 10-34% |
| Survodutide (0.6-4.8 mg SC OW) | 34-65% | 9-35% | 18-28% | 12-26% | 0-8% | 10-30% |
| Cagrisema (2.4 mg/2.4 mg SC OW) | 50-83% | 0-75% | 0-38% | - | 0-13% | 0-8% |
| Danuglipron (40-200 mg PO BD) | 7-33% | 0-25% | 4-18% | - | 1-8% | 3-34% |
FAQ: Weight Loss Medications – Semaglutide, Tirzepatide, and Retatrutide
How do the doses of these medications impact weight loss and side effects?
Higher doses of each medication generally result in greater weight loss but also increase the likelihood of side effects. For instance, Retatrutide at higher doses (8-12 mg) shows the highest weight loss (up to 24.2%) but also a broader range of side effects like nausea and vomiting. Tirzepatide (5-15 mg) and Semaglutide (50 mg) also follow this pattern, with higher doses enhancing effectiveness but increasing side effects.
Why might someone choose Tirzepatide over Semaglutide?
Tirzepatide provides substantial weight loss (16-22.5%) with less frequent dosing (once weekly) compared to Semaglutide's daily dosing. Additionally, Tirzepatide’s dual action on GLP-1 and GIP receptors may offer improved metabolic benefits and weight loss effectiveness.
What makes Retatrutide stand out among these medications?
Retatrutide shows the highest potential weight loss, up to 24.2%, especially at higher doses. Its flexible dosing options (1-12 mg) allow for adjustments based on patient tolerance, making it a versatile choice. However, the higher incidence of side effects at the upper dose range requires careful management.
Are there any specific considerations for managing side effects with these medications?
Yes, managing side effects often involves dose adjustments and supportive care measures. For example, starting at a lower dose and gradually increasing can help mitigate nausea and vomiting. Ensuring adequate hydration and dietary adjustments can help manage gastrointestinal side effects like diarrhea and constipation.
How does the administration method influence patient preference and adherence?
The administration method significantly affects patient preference. Daily oral dosing of Semaglutide may be less convenient for some, while weekly injections of Tirzepatide and Retatrutide are preferred by those looking for less frequent dosing. Individual preferences and lifestyle considerations play a crucial role in choosing the most suitable medication.
Can these medications be used for conditions other than weight loss?
A: Yes, both Semaglutide and Tirzepatide are also approved for managing type 2 diabetes due to their glucose-lowering effects. This dual benefit makes them attractive options for patients looking to address both weight and blood sugar levels. Retatrutide is currently focused on weight loss but may have potential for broader metabolic benefits.